Inhibikase Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Inhibikase Therapeutics, Inc. (IKT) reported Increase (Decrease) in Deferred Revenue of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2023-11-14
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2023-09-30 was $0.00.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was -$23.68K.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was -$1.00.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2022-06-30 was $23.68K.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $0.00.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2021 was -$2.33M, a 359.25% decline from fiscal 2020.
- Inhibikase Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2020 was $897.11K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | -$23.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$23.68K derived: sum of 2 quarters · filed 2023-11-14 | $0.00 derived: sum of 3 quarters · filed 2023-11-14 | $0.00 10-K · filed 2023-03-31 |
| 2022-09-30 | -$1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $23.68K derived: sum of 2 quarters · filed 2023-11-14 | $23.68K 10-Q · filed 2023-11-14 | $23.68K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $23.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $23.68K 10-Q · filed 2023-08-14 | $23.68K derived: sum of 3 quarters · filed 2023-08-14 | -$118.94K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | -$142.62K derived: sum of 3 quarters · filed 2023-03-31 | -$1.25M derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$142.62K derived: sum of 2 quarters · filed 2023-03-31 | -$1.25M derived: sum of 3 quarters · filed 2023-03-31 | -$2.33M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$142.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.25M derived: sum of 2 quarters · filed 2022-11-14 | -$2.33M 10-Q · filed 2022-11-14 | -$1.96M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$2.18M 10-Q · filed 2022-08-12 | -$1.82M derived: sum of 3 quarters · filed 2022-08-12 | -$1.37M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$1.07M 10-Q · filed 2022-05-16 | -$707.21K derived: sum of 2 quarters · filed 2022-05-16 | -$260.80K derived: sum of 3 quarters · filed 2022-05-16 | -$220.24K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $367.19K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $813.60K derived: sum of 2 quarters · filed 2022-03-31 | $854.15K derived: sum of 3 quarters · filed 2022-03-31 | $897.11K 10-K · filed 2022-03-31 |
| 2020-09-30 | $446.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $486.97K derived: sum of 2 quarters · filed 2021-11-15 | $529.92K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $40.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $83.51K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $42.95K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |